References
- Baker L RI, Muri J W, Sharman V L, Abrams S ML, Greenwood R N, Cattell W R, Goodwin F J, Marsh F P, Adami S, Hately W, Hattersley L A, Morgan A G, Papapoulos S E, Revell P A, Tucker A K, Chaput de Saintonge D M, Riordan J LH. Controlled trial of calcitriol in hemodialysis patient. Clin Nephrol 1986; 26: 185–191
- John Brown AM, Goodwin F J, Hately W, Marsh F P, Riordan J LH, Papapoulos S E. 1-alpha-hydroxycholecalciferol for renal osteodystrophy. Br Med J 1977; 2: 721–723
- Canalis E. Effects of hormones and growth factors on alkaline phosphatase activity and collagen synthesis in cultured rat calvariae. Metabolism 1988; 32: 14–20
- Charles P, Mosekilde L, Jensen Taagehoj F. Primary hyperparathyroidism: evaluated by 47Calcium kinetics; calcium balance and serum bone-Gla-protein. Eur J Clin Invest 1986; 16: 277–283
- Dauphine R T, Riggs B L, Scholz D A. Back pain and vertebral fractures. An unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975; 83: 365–367
- Eriksen E F, Mosekiilde L, Melsen F. Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone 1986; 7: 213–221
- Jensen Finn G, Christiansen C, Transböl I. Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen; 1.25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol 1982; 16: 515–524
- Kanis J A, Russell R GG, Cundy T, Earnshaw M, Woods C G, Smith R, Heynen G. An evaluation of 1-alpha-hydroxy- and 1.25-dihydroxyvitamin D3 in the treatment of renal bone disease. Contr Nephrol 1980; 18: 12–28
- Larsson K, Lindh E, Lind L, Persson I, Ljunghall S. Increased fracture risk in hypercalcemia. Bone mineral content measured in hyperparathyroidism. Acta Orthop Scand 1989; 60: 268–270
- Lind L, Wengle B, Wide L, Wrege U, Ljunghall S. Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis—a pilot study. Nephron 1988; 48: 296–299
- Lind L, Wengle B, Sörensen O H, Wide L, Åkerström G, Ljunghall S. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism. Acta Endocrinol 1989; 120: 250–256
- Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sörensen O H, Wide L. Treatment with one-alphahydroxycholecalciferol in middle-aged men with impaired glucose tolerance—a prospective randomized double-blind study. Acta Med Scand 1987; 222: 361–367
- Ritz E, Prager P, Krempien B, Bommer J, Malluche H H, Schmidt-Gayk H. Skeletal X-ray findings and bone histology in patients on hemodialysis. Kidney Internat 1978; 13: 316–323
- Silve C M, Hradkik G, Jones A, Arnaud C D. Parathyroid hormone receptors in intact bone, identification and cellular localization. Calcif Tissue Int 1981; 33: 325 A
- Tibi L, Collier A, Patrich A W, Clarke B F, Smith A F. Plasma alkaline phosphatase isoenzymes in diabetes mellitus. Clin Chim Acta 1988; 177: 147–156
- Tjellesen L, Christiansen C, Rödbro P. Effect of 1.25-dihydroxyvitamin D3 on biochemical indices of bone turnover in postmenopausal women. Acta Med Scand 1984; 215: 411–415